# Effect of Hepatitis C Virus Genotype, Cirrhosis, and Viral Cure on Serum Phosphatidylinositol Species Profiles

**Authors:** Kilian Weigand, Georg Peschel, Marcus Höring, Sabrina Krautbauer, Gerhard Liebisch, Martina Müller, Christa Buechler

PMC · DOI: 10.3390/biomedicines13112720 · 2025-11-06

## TL;DR

This study shows that curing hepatitis C virus (HCV) changes certain fat-like molecules in the blood, but only in patients without severe liver damage.

## Contribution

The study identifies how HCV infection and treatment affect specific phosphatidylinositol species in serum, particularly in non-cirrhotic patients.

## Key findings

- Serum PI species profiles changed in non-cirrhotic patients after HCV treatment but not in those with cirrhosis.
- Genotype 3a was linked to lower levels of specific PI species that remained reduced after treatment.
- Changes in PI species were not correlated with standard liver injury markers.

## Abstract

Background/Objectives: Phosphatidylinositol (PI) species are bioactive lipids implicated in liver fibrogenesis. Hepatitis C virus (HCV) relies on host lipid metabolism for infection. The relationship between serum PI profiles, chronic HCV, and liver injury remains incompletely defined. Methods: Fourteen PI species were quantified by direct flow injection–tandem mass spectrometry (FIA–MS/MS; triple quadrupole) in serum from 178 patients with chronic HCV at three time points: before treatment and at weeks 4 and 12 after starting direct-acting antiviral (DAA) therapy. Results: At baseline, PI 34:1, 36:1, and 36:3 were higher in patients with ultrasound-diagnosed cirrhosis than in those without, whereas PI 38:4, 40:5, and 40:6 were lower. In non-cirrhotic patients, PI 36:3, 36:4, 38:3, 38:4, and 38:5 increased, while PI 40:5 and 40:6 declined at weeks 4 and 12 after therapy start. In cirrhosis, viral cure was not associated with changes in PI species. By the end of therapy, cirrhotic patients showed higher PI 36:3 and lower PI 38:4 than non-cirrhotic patients. Genotype 3a was associated with lower PI 38:3, 38:4, and 38:5; the reduction in PI 38:4 persisted to the end of therapy. Across time points, most PI species did not correlate with routine markers of liver injury or inflammation. Conclusions: HCV cure remodels the serum PI profile in non-cirrhotic patients. These findings suggest that altered PI profiles are primarily linked to HCV infection, supporting a role for PI lipids in viral propagation.

## Linked entities

- **Diseases:** cirrhosis (MONDO:0005155)

## Full-text entities

- **Diseases:** inflammation (MESH:D007249), Cirrhosis (MESH:D005355), cirrhotic (MESH:D000094724), liver fibrogenesis (MESH:D017093), infection (MESH:D007239)
- **Chemicals:** lipid (MESH:D008055), DAA (-), PI (MESH:D010716)
- **Species:** Homo sapiens (human, species) [taxon 9606], HCV [taxon 11103]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12649964/full.md

---
Source: https://tomesphere.com/paper/PMC12649964